Unicycive Therapeutics Inc
UNCY4.204USD
+0.114+2.78%
Trading geöffnet （ET）Kurse um 15 Minuten verzögert
59.32MMarktkapitalisierung
VerlustKGV TTM
mehr Informationen über Unicycive Therapeutics Inc Unternehmen
Unicycive Therapeutics, Inc. is a biotechnology company that is developing treatments for certain medical conditions. Its programs are focused on kidney disease, an area that has the potential to offer medical benefits. Its development programs are focused on two novel therapies: Oxylanthanum Carbonate, and UNI 494. Oxylanthanum Carbonate is a novel investigational phosphate binding agent being developed for the treatment of hyperphosphatemia in chronic kidney disease patients on dialysis. UNI-494 is a patent-protected new chemical entity in clinical development for the treatment of conditions related to acute kidney injury. Oxylanthanum Carbonate and UNI 494 were initially developed by and licensed to it from Spectrum Pharmaceuticals (Spectrum) and Sphaera Pharma, respectively.
Unternehmensinformationen
BörsenkürzelUNCY
Name des UnternehmensUnicycive Therapeutics Inc
IPO-datumJun 17, 2021
CEODr. Shalabh Gupta, M.D.
Anzahl der mitarbeiter22
WertpapierartOrdinary Share
GeschäftsjahresendeJun 17
Addresse4300 El Camino Real, Suite 210
StadtLOS ALTOS
BörseNASDAQ Capital Market Consolidated
LandUnited States of America
Postleitzahl94022
Telefon16503840642
Websitehttps://unicycive.com/
BörsenkürzelUNCY
IPO-datumJun 17, 2021
CEODr. Shalabh Gupta, M.D.
Führungskräfte
Name
Name/Position
Position
Aktienbesitz
Veränderung
Dr. Sandeep (Steve) Laumas, M.D.
Dr. Sandeep (Steve) Laumas, M.D.
Independent Director
Independent Director
10.58K
--
Dr. Pramod Gupta, Ph.D.
Dr. Pramod Gupta, Ph.D.
Executive Vice President - Pharmaceutical and Business Operations
Executive Vice President - Pharmaceutical and Business Operations
4.18K
--
Dr. Shalabh Gupta, M.D.
Dr. Shalabh Gupta, M.D.
Chairman of the Board, President, Chief Executive Officer, Founder
Chairman of the Board, President, Chief Executive Officer, Founder
--
--
Mr. John Townsend
Mr. John Townsend
Chief Financial Officer
Chief Financial Officer
--
--
Mr. Doug Jermasek
Mr. Doug Jermasek
Executive Vice President - Corporate Strategy
Executive Vice President - Corporate Strategy
--
--
Dr. Gaurav Aggarwal, M.D.
Dr. Gaurav Aggarwal, M.D.
Independent Director
Independent Director
--
--
Dr. Saraswati (Sara) Kenkare-Mitra, Ph.D.
Dr. Saraswati (Sara) Kenkare-Mitra, Ph.D.
Independent Director
Independent Director
--
--
Name
Name/Position
Position
Aktienbesitz
Veränderung
Dr. Sandeep (Steve) Laumas, M.D.
Dr. Sandeep (Steve) Laumas, M.D.
Independent Director
Independent Director
10.58K
--
Dr. Pramod Gupta, Ph.D.
Dr. Pramod Gupta, Ph.D.
Executive Vice President - Pharmaceutical and Business Operations
Executive Vice President - Pharmaceutical and Business Operations
4.18K
--
Dr. Shalabh Gupta, M.D.
Dr. Shalabh Gupta, M.D.
Chairman of the Board, President, Chief Executive Officer, Founder
Chairman of the Board, President, Chief Executive Officer, Founder
--
--
Mr. John Townsend
Mr. John Townsend
Chief Financial Officer
Chief Financial Officer
--
--
Mr. Doug Jermasek
Mr. Doug Jermasek
Executive Vice President - Corporate Strategy
Executive Vice President - Corporate Strategy
--
--
Dr. Gaurav Aggarwal, M.D.
Dr. Gaurav Aggarwal, M.D.
Independent Director
Independent Director
--
--
Umsatzaufteilung
Keine Daten
Keine Daten
Nach Geschäftsbereich
Nach Region
Keine Daten
Aktionärsstatistik
Aktualisiert: Tue, Aug 19
Aktualisiert: Tue, Aug 19
Aktionäre
Aktionärstypen
Aktionäre
Aktionäre
Anteil
Vivo Capital, LLC
6.44%
Octagon Capital Advisors LP
5.66%
Nantahala Capital Management, LLC
5.32%
Great Point Partners, LLC
4.51%
The Vanguard Group, Inc.
3.43%
Andere
74.64%
Aktionäre
Aktionäre
Anteil
Vivo Capital, LLC
6.44%
Octagon Capital Advisors LP
5.66%
Nantahala Capital Management, LLC
5.32%
Great Point Partners, LLC
4.51%
The Vanguard Group, Inc.
3.43%
Andere
74.64%
Aktionärstypen
Aktionäre
Anteil
Hedge Fund
24.67%
Venture Capital
12.61%
Individual Investor
4.93%
Investment Advisor
4.75%
Investment Advisor/Hedge Fund
0.73%
Research Firm
0.19%
Andere
52.11%
Institutionelle Beteiligung
Aktualisiert: Tue, Jul 1
Aktualisiert: Tue, Jul 1
Berichtszeitraum
Anzahl der Institutionen
Gehaltenen Aktien
Anteil
Veränderung
2025Q2
62
6.96M
54.51%
-655.75K
2025Q1
65
6.78M
64.49%
-1.12M
2024Q4
62
69.04M
66.51%
+542.97K
2024Q3
57
54.12M
55.45%
+17.71M
2024Q2
48
26.33M
50.66%
-3.75M
2024Q1
46
28.58M
99.15%
+4.37M
2023Q4
45
24.82M
96.62%
+1.55M
2023Q3
47
22.73M
96.91%
+9.25M
2023Q2
42
9.36M
61.47%
-512.55K
2023Q1
38
9.94M
65.95%
+1.31M
Mehr Anzeigen
Aktionärsaktivitäten
Name
Gehaltenen Aktien
Anteil
Veränderung
Änderung%
Datum
Vivo Capital, LLC
1.14M
8.9%
+140.00K
+14.04%
Mar 31, 2025
Octagon Capital Advisors LP
1.00M
7.83%
--
--
Mar 31, 2025
Nantahala Capital Management, LLC
939.20K
7.36%
-100.00K
-9.62%
Mar 31, 2025
Great Point Partners, LLC
1.10M
8.6%
--
--
Mar 31, 2025
The Vanguard Group, Inc.
121.24K
0.95%
+7.42K
+6.52%
Mar 31, 2025
Gupta (Shalabh K)
597.25K
4.68%
-100.00
-0.02%
Apr 30, 2025
Logos Global Management LP
507.89K
3.98%
--
--
Mar 31, 2025
Rosalind Advisors, Inc.
242.49K
1.9%
+242.49K
--
Apr 30, 2025
Armistice Capital LLC
97.60K
0.76%
--
--
Dec 31, 2023
Acuta Capital Partners, LLC
235.29K
1.84%
+4.99K
+2.17%
Mar 31, 2025
Mehr Anzeigen
Verbundene ETFs
Aktualisiert: Wed, Aug 6
Aktualisiert: Wed, Aug 6
Name
Anteil
iShares Micro-Cap ETF
0%
iShares Micro-Cap ETF
Anteil0%
Dividende
In den vergangenen 5 Jahren wurden insgesamt
0.00
USD an Dividenden ausgeschüttet.
Datum
Dividende
Stichtag für die Aktienregistrierung
Zahltag
Ex-Dividendentag
Keine Daten
Aktien-Split
Datum
Art
Verhältnis
Keine Daten
Datum
Art
Verhältnis
Keine Daten
